Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase I trial is studying the side effects and best dose of oxaliplatin and etoposide in treating young patients with recurrent or refractory solid tumors or lymphomas. Drugs used in chemotherapy, such as oxaliplatin and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Oxaliplatin may also help etoposide work better by making cancer cells more sensitive to the drug. Giving oxaliplatin together with etoposide may kill more cancer cells.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

NCT00101270

Childhood Burkitt Lymphoma Childhood Central Nervous System Germ Cell Tumor Childhood Diffuse Large Cell Lymphoma +26 more

COMPLETED PHASE1

Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors

NCT00281944

Childhood Central Nervous System Choriocarcinoma Childhood Central Nervous System Embryonal Tumor Childhood Central Nervous System Germ Cell Tumor +7 more

COMPLETED PHASE1

Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors

NCT00024284

Unspecified Childhood Solid Tumor, Protocol Specific

COMPLETED PHASE1

Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment

NCT00091182

Childhood Central Nervous System Germ Cell Tumor Childhood Extragonadal Germ Cell Tumor Childhood Hepatoblastoma +23 more

COMPLETED PHASE2

Oxaliplatin in Treating Children With Advanced Solid Tumors

NCT00005844

Unspecified Childhood Solid Tumor, Protocol Specific

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose of oxaliplatin and etoposide in pediatric patients with recurrent or refractory solid tumors or lymphoma.

II. Determine the dose-limiting toxic effects of this regimen in these patients.

SECONDARY OBJECTIVES:

I. Determine the pharmacokinetic profile of this regimen in these patients. II. Correlate the extent of oxaliplatin and etoposide exposure with toxic effects and therapeutic effects of this regimen in these patients.

III. Determine, preliminarily, the antitumor activity of this regimen in these patients.

OUTLINE: This is a dose-escalation study.

Patients receive oxaliplatin IV over 2 hours on day 1 and etoposide IV over 1 hour on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of oxaliplatin and etoposide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Angioimmunoblastic T-cell Lymphoma B-cell Childhood Acute Lymphoblastic Leukemia B-cell Chronic Lymphocytic Leukemia Childhood Burkitt Lymphoma Childhood Diffuse Large Cell Lymphoma Childhood Grade III Lymphomatoid Granulomatosis Childhood Immunoblastic Large Cell Lymphoma Childhood Nasal Type Extranodal NK/T-cell Lymphoma Hepatosplenic T-cell Lymphoma Intraocular Lymphoma Noncutaneous Extranodal Lymphoma Peripheral T-cell Lymphoma Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Anaplastic Large Cell Lymphoma Recurrent Childhood Grade III Lymphomatoid Granulomatosis Recurrent Childhood Large Cell Lymphoma Recurrent Childhood Lymphoblastic Lymphoma Recurrent Childhood Small Noncleaved Cell Lymphoma Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma Recurrent Mycosis Fungoides/Sezary Syndrome Recurrent/Refractory Childhood Hodgkin Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Hairy Cell Leukemia Small Intestine Lymphoma T-cell Childhood Acute Lymphoblastic Leukemia T-cell Large Granular Lymphocyte Leukemia Unspecified Childhood Solid Tumor, Protocol Specific

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I

Patients receive oxaliplatin IV over 2 hours on day 1 and etoposide IV over 1 hour on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Group Type EXPERIMENTAL

oxaliplatin

Intervention Type DRUG

Given IV

etoposide

Intervention Type DRUG

Given IV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

oxaliplatin

Given IV

Intervention Type DRUG

etoposide

Given IV

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

1-OHP Dacotin Dacplat Eloxatin L-OHP EPEG VP-16 VP-16-213

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Life expectancy \> 8 weeks
* Albumin \> 2 g/dL
* Histologically confirmed diagnosis of 1 of the following: solid tumor; histologic verification not required for brainstem tumors or optic pathway tumors; lymphoma; recurrent or refractory to conventional therapy OR no known effective therapy exists; bone marrow involvement allowed
* Performance Status: Karnofsky \>= 50 % (patients \> 10 years of age) OR Lansky \>= 50% (patients for =\< 10 years of age)
* Absolute neutrophil count \> 1,000/mm\^3
* Platelet count \> 100,000/mm\^3 (transfusion independent)
* Hemoglobin \> 8 g/dL (transfusion allowed)
* ALT \< 5.0 times ULN
* Creatinine normal OR glomerular filtration rate \>= 80 mL/min/1.73 m\^2
* Calcium normal (electrolyte supplements allowed)
* Echocardiogram and EKG normal
* Shortening fraction \>= 27% OR ejection fraction \> 50%
* No evidence of dyspnea at rest
* No exercise intolerance
* Pulse oximetry \> 94% on room air
* Neurologic deficits due to CNS tumor must be relatively stable for \>= 2 weeks before study entry
* Seizure disorder allowed provided well-controlled by non-enzyme-inducing anticonvulsants
* No peripheral neurotoxicity \> grade 1
* Sodium, potassium, and magnesium normal (electrolyte supplements allowed)
* At least 1 week since prior biologic agents
* More than 1 week since prior growth factors
* More than 6 months since prior allogeneic peripheral blood stem cell transplantation AND no active graft-versus-host disease
* More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)
* More than 2 weeks since prior focal radiotherapy for symptomatic metastatic sites
* More than 6 weeks since prior substantial bone marrow radiotherapy
* More than 3 months since prior craniospinal (\> 24 Gy), whole pelvis, or total-body radiotherapy
* Recovered from all prior therapy
* No concurrent enzyme-inducing anticonvulsants, including, but not limited to, the following: Barbiturates; Phenytoin; Carbamazepine

Exclusion Criteria

* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No uncontrolled infection
* No history of life-threatening hypersensitivity to platinum-containing agents
* No prior oxaliplatin
* No other concurrent investigational agents
* No other concurrent anticancer therapy
* Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.

Maximum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No